Table 1 Demographic and reporting characteristics of Con-DOX and Lip-DOX AE reports in FAERS. (Con-DOX, conventional doxorubicin; Lip-DOX, liposomal doxorubicin; AE, adverse event).

From: FAERS based disproportionality analysis and network pharmacology investigation of doxorubicin associated drug induced cardiotoxicity

Characteristics

Con-DOX

Lip-DOX

Cases, n

Proportion, %

Cases, n

Proportion,%

Sex

    

Female

2089

49.9%

1680

42.63%

Male

1339

31.99%

848

21.52%

Not Specified

758

18.11%

1413

35.8%

Age, years

    

 < 18

373

8.91%

219

5.56%

18–44

728

17.39%

399

10.12%

45–64

1166

27.85%

647

16.42%

 ≥ 65

825

19.71%

538

13.65%

NotSpecified

1094

26.13%

2138

54.25%

Reporters

    

Consumer

225

5.38%

318

8.07%

Lawyer

2

0.05%

0

0

Not Specified

126

3.01%

9

0.23%

Other health-professional

806

19.25%

942

23.9%

Pharmacist(%)

1477

35.28%

729

18.5%

Physician(%)

1550

37.03%

1943

49.3%

Back to article page